S. Fine

TL;DR: This trial suggests that better palliation is achieved by using full-dose chemotherapy, and patients experienced more vomiting, myelosuppression, conjunctivitis, and alopecia when receiving higher doses of chemotherapy.

TL;DR: Thromboembolism related to the addition of CMF chemotherapy to tamoxifen as adjuvant therapy in this group of women represents a relatively common and serious complication that may outweigh any benefits offered by this additional therapy.

TL;DR: A multivariate prognostic factor analysis demonstrated that for lung cancer, the percent of weight loss, serum albumin concentration, and presence of liver metastases were significant and independent prognostic variables for survival duration and for colorectal cancer, serumalbumin, alkaline phosphatase, lactic dehydrogenase levels, and percent targeted caloric intake were significant independent predictors of survival duration.

TL;DR: Evaluation of tumors for p53 mutations may be beneficial to identify women at higher risk of disease recurrence and death when the tumor has neu/erbB-2 amplification, but in the absence of neu/, the presence of p53 mutation may not provide additional independent prognostic information.

TL;DR: The addition of CMF to TAM adds no benefit and considerable toxicity in this group of women, and there were no significant differences in overall survival, recurrence-free survival, locoregionalRecurrence- free survival, or distant recurrence -free survival between the two treatment arms.